ReviewCurrent opinion in clinical nutrition and metabolic care2018
Resveratrol for patients with chronic obstructive pulmonary disease: hype or hope?
Review in Current opinion in clinical nutrition and metabolic care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Unravelling the role of nanomedicine in attenuating inflammation, oxidative stress and cellular ageing in chronic obstructive pulmonary disease.Archives of toxicology · 2025Review
- Modulating mitochondria with natural extract compounds: from bench to clinical therapeutic opportunities for COPD.Frontiers in pharmacology · 2025Review
- Aging Lung: Molecular Drivers and Impact on Respiratory Diseases-A Narrative Clinical Review.Antioxidants (Basel, Switzerland) · 2024Review
- Chronic Obstructive Pulmonary Disease: The Role of Healthy and Unhealthy Dietary Patterns-A Comprehensive Review.Food science & nutrition · 2024Review
- Exploring the multimodal health-promoting properties of resveratrol: A comprehensive review.Food science & nutrition · 2024Review
- Construction of a ceRNA network and screening of potential biomarkers and molecular targets in male smokers with chronic obstructive pulmonary disease.Frontiers in genetics · 2024Article
- Review
- Formulation of Resveratrol-Loaded Polycaprolactone Inhalable Microspheres Using Tween 80 as an Emulsifier: Factorial Design and Optimization.AAPS PharmSciTech · 2023Article
- The Effects of Resveratrol on Silica-Induced Lung Oxidative Stress and Inflammation in Rat.Safety and health at work · 2023Article
- Aging and aging-related diseases: from molecular mechanisms to interventions and treatments.Signal transduction and targeted therapy · 2022Review
- Stimulating Mitochondrial Biogenesis with Deoxyribonucleosides Increases Functional Capacity in ECHS1-Deficient Cells.International journal of molecular sciences · 2022Article
- Black Ginseng Extract Suppresses Airway Inflammation Induced by Cigarette Smoke and Lipopolysaccharides In Vivo.Antioxidants (Basel, Switzerland) · 2022Article
- Resveratrol and Immune Cells: A Link to Improve Human Health.Molecules (Basel, Switzerland) · 2022Review
- A Review on the Antiviral Activity of Functional Foods Against COVID-19 and Viral Respiratory Tract Infections.International journal of general medicine · 2022Review
- Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- An approach of fatty acids and resveratrol in the prevention of COVID-19 severity.Phytotherapy research : PTR · 2021Article
- Immunomodulatory Role of Nutrients: How Can Pulmonary Dysfunctions Improve?Frontiers in nutrition · 2021Review
- Age-related mitochondrial dysfunction as a key factor in COVID-19 disease.Experimental gerontology · 2020Review
- Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewChronic obstructive pulmonary disease (COPD) is a progressive lung disease with a high prevalence of extrapulmonary manifestations and, frequently, cardiovascular comorbidity. Resveratrol is a food-derived compound with anti-inflammatory, antioxidant, metabolic and cardioprotective potential. Therefore, resveratrol might improve the pulmonary as well as extrapulmonary pathology in COPD. In this review, we will evaluate knowledge on the effects of resveratrol on lung injury, muscle metabolism and cardiovascular risk profile and discuss if resveratrol is a hype or hope for patients with COPD. RECENT
findingsExperimental models of COPD consistently show decreased inflammation and oxidative stress in the lungs after resveratrol treatment. These beneficial anti-inflammatory and antioxidant properties of resveratrol can indirectly also improve both skeletal and respiratory muscle impairment in COPD. Recent clinical studies in non-COPD populations show improved mitochondrial oxidative metabolism after resveratrol treatment, which could be beneficial for both lung and muscle impairment in COPD. Moreover, preclinical studies suggest cardioprotective effects of resveratrol but results of clinical studies are inconclusive. SUMMARY: Resveratrol might be an interesting therapeutic candidate to counteract lung and muscle impairments characteristic to COPD. However, there is no convincing evidence that resveratrol will significantly decrease the cardiovascular risk in patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.